• Home
  • News
  • Fortune 500
  • Tech
  • Finance
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
HealthCOVID-19 vaccines

China’s Sinovac says its vaccine is safe and effective for children

By
The Associated Press
The Associated Press
By
The Associated Press
The Associated Press
March 23, 2021, 10:23 AM ET

Sinovac said on Monday that its COVID-19 vaccine CoronaVac is safe and effective in children ages 3-17.

The results were from early and mid-stage clinical trials with over 550 subjects, said Geng Zeng, the medical director at Sinovac, at a press conference.

While the vaccine has already been allowed for use in adults in China, further testing was needed to see how it would work with children.

More than 70 million shots of Sinovac’s vaccine has been given worldwide, including in China.

There were two instances of high fevers in response to the vaccine during trials, one in a 3-year old participant and the other in a six-year old. The rest of the participants had experienced mild symptoms, said Geng.

State-owned Sinopharm, who has two COVID-19 vaccines, is also investigating the effectiveness of its vaccines in children. They had said in January that they submitted clinical data to regulators, though it was unclear if it was for both of their shots or just one.

About the Author
By The Associated Press
See full bioRight Arrow Button Icon
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.